Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
1997-04-23
2001-03-27
Graser, Jennifer (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C042S096000, C042S094000, C042S094000, C042S130000, C042S130000, C042S130000, C042S130000, C042S130000, C042S130000, C042S130000, C435S071100, C435S097000, C435S197000, C435S252300
Reexamination Certificate
active
06207157
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to conjugate vaccines for prevention of bacterial infections. More specifically, the invention relates to a conjugate vaccine for nontypeable
Haemophilus influenzae
comprising lipooligosaccharide from which esterified fatty acids have been removed linked to an immunogenic carrier.
BACKGROUND OF THE INVENTION
Nontypeable
Haemophilus influenzae
(NTHi) is a major causative agent for acute otitis media (middle ear infections) and respiratory infections. Acute otitis media and otitis media with effusion are common childhood diseases, second in frequency of occurrence only to the common cold (Stool et al.,
Pediatr. Infect. Dis. Suppl
., 8:S11-S14, 1989). The annual cost of the medical and surgical treatment of otitis media in the United States is estimated at between three and four billion dollars (Berman,
New Engl. J. Med
., 332:1560-1565, 1995). Moreover, inappropriate antibiotic treatment of otitis media can lead to the emergence of multidrug-resistant bacterial strains. There is currently no vaccine available for prevention of NTHi infection.
Current efforts in developing an NTHi vaccine are focused on cell surface antigens such as outer membrane proteins and pili or fimbria (Kyd et al.,
Infect. Immun
., 63:2931-2940, 1995; Deich et al.,
Vaccine Res
., 2:31-39, 1995). Among these, the most promising is P6 protein which appears to be antigenically conserved and elicits the production of antibodies that are bactericidal in vitro. Lipooligosaccharide (LOS) is a major NTHi cell surface antigen. LOS contains both lipid A and oligosaccharide (OS) components. Because the lipid A component of LOS is toxic, it must be detoxified prior to conjugation to an immunogenic carrier.
Barenkamp et al. (
Pediafr. Infect. Dis. J
., 9:333-339, 1990) demonstrated that LOS stimulated the production of bactericidal antibodies directed against NTHi. McGehee et al. (
Am. Journal Respir. Cell Biol
., 1:201-210, 1989) showed that passive immunization of mice with monoclonal antibodies directed against LOS from NTHi enhanced the pulmonary clearance of NTHi.
Green et al. (
Vaccines
, 125-129, 1994) disclose an NTHi vaccine comprising a conjugate of NTHi OS and the mutant nontoxic diphtheria protein CRM
197
. The lipid A moiety was removed from LOS by treatment with acid, followed by derivatizing the resulting OS with adipic acid dihydrazide (ADH) and coupling to CRM
197
. Despite the showing of Barenkamp et al. that LOS stimulated production of bactericidal antibodies against NTHi, the conjugates of Green et al. were determined to be poorly imnmunogenic after injection into mice. Moreover, the conjugates did not elicit bactericidal antibodies against NTHi.
Thus, there is a need for a vaccine effective against NTHi. The present invention satisfies this need.
SUMMARY OF THE INVENTION
One embodiment of the present invention is a conjugate vaccine for nontypeable
Haemophilus influenzae
(NTHi), comprising NTHi lipooligosaccharide from which esterified fatty acids have been removed (dLOS), and an immunogenic carrier covalently linked thereto. In another aspect of the present invention, the immunogenic carrier is a protein. Preferably, the protein is tetanus toxin/toxoid, NTH high molecular weight protein, diphtheria toxin/toxoid, detoxified
P. aeruginosa
toxin A, cholera toxin/toxoid, pertussis toxin/toxoid,
Clostridium perfringens
exotoxins/toxoid, hepatitis B surface antigen, hepatitis B core antigen, rotavirus VP 7 protein, or respiratory syncytial virus F and G protein. Most preferably, the protein is tetanus toxoid or NTHi high molecular weight protein.
The present invention also provides a conjugate vaccine for nontypeable
Haemophilus influenzae
(NTHi), comprising NTHi lipooligosaccharide from which esterified fatty acids have been removed (dLOS), and an immunogenic carrier covalently linked thereto via a linker. Preferably, the linker is adipic acid dihydrazide, e-aminohexanoic acid, chlorohexanol dimethyl acetal, D-glucuronolactone or p-nitrophenylamine; most preferably, the linker is adipic acid dihydrazide.
Another embodiment of the invention is isolated NTHi lipooligosaccharide detoxified by removal of ester-linked fatty acids therefrom.
The present invention also provides a pharmaceutical composition comprising the vaccine conjugates described above in a pharmaceutically acceptable carrier. The pharmaceutical composition may further comprise an adjuvant. Preferably, the adjuvant is alum.
Another embodiment of the invention is a method of preventing otitis media caused by NTHi in a mammal, comprising administering to the mammal an effective immunoprotective amount of the vaccine described above. Preferably, the mammal is a human. The route of administration may be intramuscular, subcutaneous, intraperitoneal, intraarterial, intravenous or intranasal; most preferably, the administering step is intramuscular. According to another aspect of this preferred embodiment, the effective dose is between about 10 &mgr;g and about 50 &mgr;g. The method may further comprise injecting between about 10 &mgr;g and about 25 &mgr;g at about 2 months and at about 13 months after the administering step. Alternatively, the method may further comprise injecting between about 10 &mgr;g and about 25 &mgr;g at about 2, 4 and 16 months after the administering step.
According to another aspect of the invention, there is provided a method of detoxifing lipooligosaccharide from NTHi, comprising removing ester-linked fatty acids therefrom. Preferably, the ester-linked fatty acids are removed by treating the LOS with hydrazine.
Still another aspect of the present invention is a method of making a conjugate vaccine against NTHi, comprising:
removing ester-linked fatty acids from NTHi lipooligosaccharide to produce dLOS; and
covalently binding said dLOS to an immunogenic carrier.
Advantageously, the removing step comprises treatment with hydrazine. The method may further comprise the step of attaching dLOS to a linker and attaching the linker to the carrier. Preferably, the linker is adipic acid dihydrazide, &egr;-aminohexanoic acid, chlorohexanol dimethyl acetal, D-glucuronolactone or p-nitrophenylethyl amine; most preferably, the linkaer is adipic acid dihydrazide.
REFERENCES:
patent: 4619828 (1986-10-01), Gordon
patent: 5013661 (1991-05-01), Munford et al.
patent: 5153312 (1992-10-01), Porro
patent: 5204098 (1993-04-01), Szu et al.
patent: 5506139 (1996-04-01), Loosmore et al.
patent: 5601831 (1997-02-01), Green et al.
patent: 5696000 (1997-12-01), Krivan et al.
patent: 0245045 (1987-01-01), None
patent: 0 245 045 A2 (1987-11-01), None
patent: 0 497 525 A2 (1992-05-01), None
Barenkamp, S. 1996. Immunization with High-Molecular-Weight Adhesion Proteins of NntypeableHaemophilus influenzaeModifies Experimental Otitis Media in Chinchillas. Infection and Immunity. 64 (4): 1246-1251.*
Green et al. 1994. NontypeableHaemophilus influenzaeLipo-oligosacchrides conjugates as Vaccine candidates against NTHi. Vaccines. pp. 12-129.*
Erwin et al. 1991. Infection and Immunity. 59(6): 1881-1887.*
Green et al. 1994. Vaccine. 94:125-129.*
Gu et al. 1995. Infection and Immunity. 63(10): 4115-4120.*
Gu et al. 1996. Infection and Immunity. 64(10): 4047-4053.*
Patrick et al. 1987. Infection and Immunity. 55(12): 2902-2911.*
Gibson et al. 1993. J. of Bacter. 175(0): 2702-2712.*
Helander et al. 1988. Eur. J. of Biochem. 177:483-492.*
Kondau et al. 1996. Infect. and Immun. 64(7): 2709-2715.*
Phillips et al. 1992. Biochem. 31:4515-4526.*
S.J. Barenkamp, M.D., et al., “Development of serum bactericidal activity following nontypableHaemophilus influenzaeacute otitis media,”Pediatr. Infect. Dis. J.9(5):333-339 (1990).
S.J. Barenkamp, M.D., et al., “Immunization with High-Molecular-Weight Adhesion Proteins of NontypeableHaemophilus influenzaeModifies Experimental Otitis Media in Chinchillas,”Infection and Immuntiy64(4):1246-1251 (1996).
S. Berman, M.D., “Otitis Media In Children,”The New England Journal of Medicine332(23):1560-1565 (1995).
W.J. Black et al., “ADP-Ribosyltransferase Activity o
Gu Xin-Xing
Lim David J.
Robbins John B.
Tsai Chao-Ming
Graser Jennifer
Hines Ja-Na A.
Knobbe Martens Olson & Bear LLP
The United States of America as represented by the Department of
LandOfFree
Conjugate vaccine for nontypeable Haemophilus influenzae does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugate vaccine for nontypeable Haemophilus influenzae, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugate vaccine for nontypeable Haemophilus influenzae will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2496789